Get Adobe Flash player Install latest flash player if you can't see this gallery.

Anticoagulants in Cancer-Associated Thrombosis
Dr. Khorana of the Cleveland Clinic describes his recent study analyzing current thromboprophylaxis practices and patient persistence on therapies in a real-world setting. Specific consideration is given to cancer patients at risk for thrombosis events. Dr. Khorana further discusses recent and ongoing clinical trials such as those comparing novel oral anticoagulants against low molecular weight heparins.

To expand the available knowledge of Thrombosis, supports an online community of experts and a forum for discussion.
  • Mark Crowther, MD, MSc, FRCPC
    Professor, Department of Medicine, Hematology
    and Thromboembolism and Pathology and Molecular Medicine
    McMaster University, Hamilton, Ontario, CA
  • Charles Pollack, MD
    Professor of Emergency Medicine and Associate Provost
    Thomas Jefferson University
    Philadelphia, PA

Are the results of the CATCH study generalizable across all LMWH? | Generally, the LMWH’s as a class are considered equally safe and effective....
More >>
What was the actual bridging protocol utilized for the medications administered in the BRIDGE study? | Per the publication, warfarin treatment was stopped 5 days before the procedure, and administration of dalteparin (or matching placebo) was started 3 days before the procedure....
More >>
In patients with unexplained arterial thrombosis, is screening for "latent MPD by Jak2 worthy of merit? | There does not seem to be as close of an association between JAK2 mutational status and spontaneous arterial thrombosis as there exists between JAK2 mutational status.........
More >>
What are the major shortcomings of utilizing NOACs instead of warfarin? | The lack of a reversal agent for these products ..........
More >>
In patients taking NOACs, who is at highest risk for bleeding? | A person who has had recent major bleeding or at high risk of major bleeding should be anticoagulated with extreme care...
More >>
When are antidotes for NOACs expected to be approved? | Three antidotes are currently in final stages of development, andexanet alpha, idarucizumab, and arizapine.  Pending successful clinical trial results and FDA approval, you may see the first of these agents available later this year with others in 2016. 
More >>
Get up to date on the latest thrombosis research.

ISTH 2015: Review late-breaking information from ISTH 2015, including ANNEXA, REVERSE-AD, the Bridge Study and more.

ISTH 2015 | At the ISTH Congress, thousands of the world’s leading experts on thrombosis, haemostasis and vascular biology come together to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care.